Rigel Pharmaceuticals 已就口服PROTAC药物Veppanu™(通用名:Vepdegestrant)达成了一项独家全球许可协议。该药物旨在用于治疗二线及以后(2L+)的雌激素受体阳性/人表皮生长因子受体2阴性(ER+/HER2-)、且携带雌激素受体1(ESR1)突变的晚期或转移性乳腺癌患者。
Rigel Pharmaceuticals 已就口服PROTAC药物Veppanu™(通用名:Vepdegestrant)达成了一项独家全球许可协议。该药物旨在用于治疗二线及以后(2L+)的雌激素受体阳性/人表皮生长因子受体2阴性(ER+/HER2-)、且携带雌激素受体1(ESR1)突变的晚期或转移性乳腺癌患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.